Advate is a treatment for hemophilia type A, which was developed by Shire (now part of Takeda Pharmaceuticals). Advate is also available in generic formulations from many companies.

How Advate works

Hemophilia is a blood disorder caused by the body not producing enough clotting factors — proteins in the blood that control clotting. Patients with severe hemophilia have very low levels of clotting factors, which means that their blood does not clot, making accidents and injuries very dangerous for these patients. Hemophilia type A is caused by low levels of clotting factor VIII.

Advate contains recombinant clotting factor VIII, which has been made artificially in a laboratory. It’s administered as an injection, usually by a healthcare professional in a hospital or clinic. Some patients can be trained to administer the therapy themselves at home as a prophylactic treatment, or preventive measure against bleeding. Advate may also be administered before surgical procedures to prevent excessive bleeding.

Once administered, the clotting factor contained within Advate acts to prevent bleeding episodes. However, a small percentage of patients spontaneously develop inhibitors against the clotting factor, which can prevent the treatment from working as effectively.

Advate in clinical trials

A study examining the safety and tolerability of Advate in treating hemophilia A in children and adults was published in the journal Haemophilia. The study examined data from 12 clinical trials (Phase 1 through 4) spanning more than 10 years, and included 418 patients with severe hemophilia A.

The study found that most adverse events from Advate treatment were non-serious, but of the serious adverse events, the most common were related to the development of inhibitors against factor VIII, device-related infection, and fever. No deaths or cases of hypersensitivity were observed, and the authors concluded that no new safety concerns were raised by their study.

Other information

Advate can cause side effects including fever and headache. In rare cases, patients may develop an allergic reaction to the treatment.


Hemophilia News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.